The abstract is read at the publisher; the summary is JClub's.
Brepocitinib in adults with biopsy-proven active cutaneous sarcoidosis improved CSAMI-A scores by 22.3 points (45 mg) and 22.2 points (15 mg) at week 16 versus 0.7 with placebo (P < .001).
- Why it matters: Cutaneous sarcoidosis is chronic and morbid, with no approved treatments, creating a need for targeted, effective, and well-tolerated options for affected adults.
- What they did: In the BEACON phase 2/3 randomized, double-blind, placebo-controlled trial, adults were assigned 3:2:2 to brepocitinib 45 mg, 15 mg, or placebo once daily for 16 weeks, with CSAMI-A change as the primary endpoint.
- The result: Brepocitinib 45 mg produced higher CSA-IGA clear or almost clear rates (69.2% vs 0%; P = .01), CSAMI-A response (76.9% vs 0%; P = .003), ≥10-point CSAMI-A reductions (100% vs 14.3%; P < .001), and CSAMI-A <5 (61.5% vs 0%; P = .005), with no deaths or serious adverse events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.